This article was originally published in The Gray Sheet
Executive SummaryInitial public offering of 1.2 mil. shares at $5 each is outlined in a prospectus filed with the Securities and Exchange Commission. The San Diego development-stage firm plans to file a 510(k) with FDA in May for its first product, a disposable ambulatory infusion pump. Also in the pipeline is an ear and body-piercing device. Gross proceeds of $6 mil. are tabbed for sales and marketing activities, R&D, and working capital. The firm hopes to raise enough capital to qualify for listing on the Nasdaq small-cap market
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.